The type I interferon antiviral response in the choroid plexus and the cognitive risk in COVID-19

Nat Immunol. 2023 Feb;24(2):220-224. doi: 10.1038/s41590-022-01410-z. Epub 2023 Jan 30.

Abstract

The type I interferon (IFN) response is the body's typical immune defense against viruses. Previous studies linked high expression of genes encoding type I IFNs in the brain's choroid plexus to cognitive decline under virus-free conditions in aging and neurodegeneration. Multiple reports have documented persisting cognitive symptoms following recovery from COVID-19. Cumulative evidence shows that the choroid plexus is one of the brain regions most vulnerable to infection with the coronavirus SARS-CoV-2, and manifests increased expression of genes encoding type I IFNs even in the absence of viral traces within the brain. In this Perspective, we propose that the type I IFN defensive immune response to SARS-CoV-2 infection in the choroid plexus poses a risk to cognitive function if not resolved in a timely manner.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / metabolism
  • COVID-19* / metabolism
  • Choroid Plexus / metabolism
  • Cognition
  • Humans
  • Interferon Type I* / metabolism
  • Interferons / metabolism
  • SARS-CoV-2 / physiology

Substances

  • Interferon Type I
  • Antiviral Agents
  • Interferons